A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

BACKGROUND: The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target of rapamycin inhibitor) might work synergistically. METHODS: A phase I dose-escalation study with sorafenib twice a day (b.i.d.) and sirolimus once daily (q.d.) was perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Desar, I M E, Timmer-Bonte, J N H, Burger, D M, van der Graaf, W T A, van Herpen, C M L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994217/
https://www.ncbi.nlm.nih.gov/pubmed/21045832
http://dx.doi.org/10.1038/sj.bjc.6605777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994217/
https://www.ncbi.nlm.nih.gov/pubmed/21045832
http://dx.doi.org/10.1038/sj.bjc.6605777

Ejemplares similares